Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 50268-629

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 50268-629). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 5026862715 Oxybutynin Chloride Er 2014 5mg

Label for Oxybutynin Chloride Extended-Release Tablets USP 5 mg oral tablets by AvPAK. It indicates 50 tablets packaged as 5 x 10 unit doses, Rx only. The label includes dosage strength, barcode, NDC 50268-627-15, storage instructions, and manufacturer information.*

FDA Label Image

Label 5026862815 Oxybutynin Chloride Er 2017 10mg

Label for Oxybutynin Chloride Extended-Release Tablets USP 10 mg by AvPAK. The label specifies a prescription-only oral extended-release tablet, packaged as 50 tablets in unit dose format. It includes storage instructions, dosage guidance, and manufacturer information for AvKARE, Inc.*

FDA Label Image

Label 5026862913 Oxybutynin Chloride Er 2014 15mg

Label for Oxybutynin Chloride Extended Release Tablets USP 15 mg by AvPAK. The label indicates the oral extended-release tablet dosage form, with a package containing 30 tablets (3 x 10) unit dose. It includes a barcode, storage instructions, and manufacturer information.*

FDA Label Image

Structural Formula (Oxybutynin 1)

Chemical structure of oxybutynin chloride, showing its molecular components including a cyclohexane ring, phenyl group, ester and amine functional groups, and hydrochloride salt form.*

FDA Label Image

Mean Plasma Levels (Oxybutynin 2)

A line graph comparing the mean plasma concentration of oxybutynin over 24 hours for oxybutynin chloride extended-release tablets versus oxybutynin 5 mg taken three times daily (TID). The x-axis represents time in hours, and the y-axis shows mean plasma oxybutynin concentration in ng/mL. Data points include error bars indicating variability.*

FDA Label Image

Steady State (Oxybutynin 3)

A line graph depicting the mean plasma concentration of R-Oxybutynin over time in hours. The vertical axis represents concentration in ng/mL, ranging from 0 to 2.0, and the horizontal axis shows time from 0 to 25 hours. Data points with error bars indicate concentration measurements at various time intervals up to 24 hours.*

FDA Label Image

Study 1 (Oxybutynin 4)

A horizontal error bar chart comparing mean change (±SD) in episodes per week from baseline between Oxybutynin chloride extended-release tablets and placebo. The graph displays the variation in treatment effect for Oxybutynin versus placebo.*

FDA Label Image

Study 2 (Oxybutynin 5)

A horizontal bar chart illustrating the mean change with standard deviation from baseline in episodes per week for Oxybutynin Chloride extended-release tablets. The x-axis represents the change in episodes per week from -40 to 40, with data points centered near -20, indicating a reduction in episodes.*

FDA Label Image

Study 3 (Oxybutynin 6)

A horizontal bar chart illustrating the mean change in episodes per week from baseline for oxybutynin and oxybutynin chloride extended-release tablets. The x-axis shows the mean change with a range from -40 to 40. The chart compares two treatments indicating effectiveness in reducing episodes per week.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.